Filing Details

Accession Number:
0001140361-16-081629
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-10-04 15:59:48
Reporting Period:
2016-09-30
Filing Date:
2016-10-04
Accepted Time:
2016-10-04 15:59:48
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1048477 Biomarin Pharmaceutical Inc BMRN Pharmaceutical Preparations (2834) 680397820
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1221590 Jacques Jean Bienaime C/O Biomarin Pharmaceutical Inc.
770 Lindaro St.
San Rafael CA 94901
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-09-30 53,125 $38.59 431,709 No 4 M Direct
Common Stock Disposition 2016-09-30 53,125 $92.02 378,584 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy Common Stock) Disposition 2016-09-30 53,125 $0.00 53,125 $38.59
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
265,625 2008-11-22 2018-05-21 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 25,758 Indirect Shares held by Bienaime Family Trust
Footnotes
  1. Trade made pursuant to a 10b5-1 plan executed on June 9, 2016. Mr. Bienaime's former spouse will receive the net proceeds from the shares sold in this transaction in connection with cash payments owed to her pursuant to a marital separation agreement between her and Mr. Bienaime.
  2. The price in column 4 is the weighted average price. The price actually received ranged from $91.30 to $92.91. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
  3. Reflects the number of stock options outstanding after the transaction from this specific stock option grant.